Inozyme COO Shows Confidence: Acquires $10.6K Worth of Company Stock

Rhea-AI Filing Summary

Inozyme Pharma COO Matthew Winton acquired 14,355 shares of common stock on June 25, 2025, through the company's Employee Stock Purchase Plan (ESPP). The shares were purchased at $0.74 per share, representing 85% of the closing price on April 1, 2025, the first day of the purchase period.

Following this transaction, Winton's direct beneficial ownership increased to 21,743 shares. The purchase was made during the ESPP period running from April 1, 2025, through June 25, 2025.

• Transaction Type: Stock Purchase through ESPP
• Purchase Price: $0.74 per share (15% discount)
• Ownership Form: Direct
• Filing Status: Individual filing

This insider purchase through the ESPP demonstrates continued participation in company equity programs by key executive leadership.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Winton Matthew

(Last) (First) (Middle)

C/O INOZYME PHARMA, INC.

321 SUMMER STREET SUITE 400

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Inozyme Pharma, Inc. [ INZY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	COO

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/25/2025		A(1)	V	14,355	A	$0.74	21,743	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares purchased pursuant to the Inozyme Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of April 1, 2025 through June 25, 2025. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on April 1, 2025, the first trading day of the purchase period.

	/s/ Sanjay Subramanian, as attorney-in-fact for Matthew Winton	06/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many shares of INZY stock did COO Matthew Winton purchase on June 25, 2025?

COO Matthew Winton purchased 14,355 shares of INZY common stock on June 25, 2025 through the company's Employee Stock Purchase Plan (ESPP).

What was the purchase price for INZY shares in the ESPP transaction on June 25, 2025?

The shares were purchased at $0.74 per share, which represents 85% of the closing price of Inozyme Pharma's common stock on April 1, 2025 (the first trading day of the purchase period).

How many INZY shares does Matthew Winton own after the June 25, 2025 ESPP purchase?

Following the ESPP purchase transaction, Matthew Winton directly owns 21,743 shares of INZY common stock.

What is the ESPP purchase period for INZY stock mentioned in the Form 4?

The ESPP purchase period ran from April 1, 2025 through June 25, 2025, as disclosed in the filing's explanation of responses.

Who signed the Form 4 filing for INZY's COO Matthew Winton?

The Form 4 was signed by Sanjay Subramanian as attorney-in-fact for Matthew Winton on June 27, 2025.